Nextgen Biomed Ltd
Symbool: NXGN.TA
TLV
101.8
ILAMarktprijs vandaag
-106.3909
Koers/Winst Verhouding
0.0000
Koers/Winst Groei Verhouding
7.56M
MRK Kapitalisatie
- 0.00%
DIV Rendement
Nextgen Biomed Ltd (NXGN-TA) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 5.2 | 12 | 5.7 | |||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.other-current-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-current-assets | 0 | 5.3 | 12.3 | 5.9 | |||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 1.6 | 7.3 | 0 | |||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.other-non-current-assets | 0 | 8.1 | 4.1 | 2.4 | |||||||||
balance-sheet.row.total-non-current-assets | 0 | 9.6 | 11.4 | 2.4 | |||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-assets | 0 | 14.9 | 23.6 | 8.3 | |||||||||
balance-sheet.row.account-payables | 0 | 0.2 | 0.1 | 0.1 | |||||||||
balance-sheet.row.short-term-debt | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 0 | |||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||
balance-sheet.row.other-current-liab | 0 | 1.1 | 0.6 | 1.4 | |||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 1.4 | 2.1 | 0 | |||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-liab | 0 | 2.6 | 2.9 | 1.5 | |||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.retained-earnings | 0 | -51.9 | -43.3 | -40.7 | |||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 64.2 | 64.1 | 47.7 | |||||||||
balance-sheet.row.total-stockholders-equity | 0 | 12.4 | 20.8 | 7 | |||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 14.9 | 23.6 | 8.3 | |||||||||
balance-sheet.row.minority-interest | 0 | -0.1 | -0.1 | -0.1 | |||||||||
balance-sheet.row.total-equity | 0 | 12.3 | 20.7 | 6.9 | |||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||
Total Investments | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-debt | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.net-debt | 0 | -5.2 | -12 | -5.7 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -8.6 | -2.5 | -1.3 | ||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.deferred-income-tax | 0 | 5 | -0.1 | 0 | ||||||||||
cash-flows.row.stock-based-compensation | 0 | 0.2 | 0.2 | 0 | ||||||||||
cash-flows.row.change-in-working-capital | 0 | 0.7 | 0 | -0.2 | ||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-non-cash-items | 0 | 0 | -0.1 | 0 | ||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.5 | 0 | ||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | -0.5 | ||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | -2 | -1.9 | ||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -4 | -2.5 | -2.4 | ||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 11.4 | 7 | ||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 0 | 0.7 | ||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 0 | 11.4 | 7.7 | ||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.net-change-in-cash | 0 | -6.7 | 6.3 | 3.8 | ||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 5.2 | 11.9 | 5.7 | ||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 12 | 5.7 | 1.9 | ||||||||||
cash-flows.row.operating-cash-flow | 0 | -2.8 | -2.7 | -1.5 | ||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.5 | 0 | ||||||||||
cash-flows.row.free-cash-flow | 0 | -2.8 | -3.2 | -1.5 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.gross-profit | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.other-expenses | 0 | -5 | 0 | 0 | ||||||||||
income-statement-row.row.operating-expenses | 0 | 3.6 | 2.8 | 1.3 | ||||||||||
income-statement-row.row.cost-and-expenses | 0 | 3.6 | 2.8 | 1.3 | ||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0.3 | 0 | ||||||||||
income-statement-row.row.interest-expense | 0 | 0.1 | 0 | 0 | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 0.7 | 0.3 | 0 | ||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.other-operating-expenses | 0 | -5 | 0 | 0 | ||||||||||
income-statement-row.row.total-operating-expenses | 0 | 0.7 | 0.3 | 0 | ||||||||||
income-statement-row.row.interest-expense | 0 | 0.1 | 0 | 0 | ||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.operating-income | 0 | -9.3 | -2.8 | -1.3 | ||||||||||
income-statement-row.row.income-before-tax | 0 | -8.6 | -2.6 | -1.3 | ||||||||||
income-statement-row.row.income-tax-expense | 0 | 0.8 | 0.3 | 0 | ||||||||||
income-statement-row.row.net-income | 0 | -8.6 | -2.5 | -1.3 |
Vaak gestelde vragen
Wat is Nextgen Biomed Ltd (NXGN.TA) totale activa?
Nextgen Biomed Ltd (NXGN.TA) totale activa is 14888000.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is N/A.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.000.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is 0.000.
Wat is de totale omzet van de onderneming?
De totale opbrengst is 0.000.
Wat is Nextgen Biomed Ltd (NXGN.TA) nettowinst (netto-inkomen)?
De nettowinst is -8572000.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 0.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 3581000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 0.000.